French Law Tackles Biologic Originator Tactics
Measures Form Part Of France’s Social Security Bill For 2020
France is seeking to tackle the originator tactic of using low prices for biologic brands in hospitals to snare patients and keep them on the same product once they transition to outpatient care, where prices are much higher.
You may also be interested in...
French off-patent industry association Gemme has declared a “state of emergency” for French generics as it revealed industry data for 2019 pointing to weak growth. Meanwhile, Gemme says, the country’s biosimilars market is “dynamic” and growing quickly but is still under-performing.
Biogaran says it has cemented its position as the market leader for hospital biosimilars in France, pointing to high penetration levels for biosimilars in the hospital setting in general. However, the firm says, more efforts are needed to encourage uptake in the outpatient setting, including pharmacy-level substitution.
Adrian van den Hoven, director general of Medicines for Europe, gives Generics Bulletin the industry’s viewpoint on recent action taken on barriers to biosimilar competition in Belgium, France and the Netherlands.